Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
3 "Sung Chul Lee"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Pediatric cancer
The Efficacy of Alternate Systemic Intravenous Chemotherapy and Intra-arterial Chemotherapy Approach for Eye Globe Salvage in Retinoblastoma
Jung Woo Han, Christopher Seungkyu Lee, Seung Min Hahn, Won Kee Ahn, Hyo Sun Kim, Hyeseon Yun, Sung Chul Lee, Byung Moon Kim, Dong Joon Kim, Chuhl Joo Lyu
Cancer Res Treat. 2023;55(1):270-278.   Published online May 24, 2022
DOI: https://doi.org/10.4143/crt.2021.1537
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The advances in the treatment of retinoblastoma have enabled salvaging the globe in advanced stages with intra-arterial chemotherapy (IAC). We developed a strategy of alternate application of systemic intravenous chemotherapy (IVC) and IAC (referred to as alternate systemic IVC and IAC; ASIAC) to reduce central nervous metastases during IAC and examined its efficacy and safety in eye globe salvage in this study.
Materials and Methods
Between January 2010 and February 2021, 43 eyes of 40 patients received ASIAC treatment for retinoblastoma at the Yonsei Cancer Center, Yonsei University Health System. Their medical records were reviewed retrospectively to evaluate the eye salvage rate (ESR), defined from diagnosis to enucleation. High-risk retinoblastoma was defined as group D or E by the International Classification of Retinoblastoma.
Results
The study enrolled 38 and five cases of high-risk and low-risk retinoblastoma, respectively. In total, 178 IAC and 410 IVC courses were administered, with a median of 4 (interquartile range [IQR], 3.0 to 5.0) IAC and 9 (IQR, 6.0 to 11) IVC courses per eye, respectively. The 5-year ESR was 60.4%±8.7% for the whole cohort, 100% for low-risk retinoblastoma, and 53.6%±9.8% for high-risk retinoblastoma. Among those diagnosed since 2015, the 5-year ESR for high-risk retinoblastoma was 63.5%±14.0%. Fifteen eyes underwent enucleation; no viable tumor was found in three enucleated eyes. There were no deaths in this cohort.
Conclusion
Primary IAC-IVC (i.e., ASIAC) for patients with retinoblastoma was tolerable and effective in salvaging the eye and maintaining survival.

Citations

Citations to this article as recorded by  
  • Selective ophthalmic arterial injection using a balloon catheter for retinoblastoma: a seven-year clinical evaluation
    Sota Oguro, Yi Ning Chen, Takashi Yamane, Makoto Mohri, Shigenobu Suzuki
    Japanese Journal of Ophthalmology.2024; 68(4): 346.     CrossRef
  • Hematological Second Primary Malignancy in Pediatric Retinoblastoma: A Case Report and Systematic Review
    Seung Hyun Park, Hyun Young Park, Heejin Kim, Jung Woo Han, Jin Sook Yoon
    Ophthalmic Plastic & Reconstructive Surgery.2024; 40(5): 487.     CrossRef
  • 5,365 View
  • 132 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma
Jee Hung Kim, Su-Jin Shin, Soo Jin Heo, Eun-Ah Choe, Chang Gon Kim, Minkyu Jung, Ki Chang Keum, Jin Sook Yoon, Sung Chul Lee, Sang Joon Shin
Cancer Res Treat. 2018;50(4):1238-1251.   Published online December 28, 2017
DOI: https://doi.org/10.4143/crt.2017.534
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Uveal melanoma has a very poor prognosis despite successful local primary tumor treatment. In this study, we investigated prognostic factors that more accurately reflected the likelihood ofrecurrence and survival and delineated a prognostic model that could effectively identify different risk groups based on initial clinical parameters.
Materials and Methods
Prognostic factors associated with distant recurrence, recurrence-free survival (RFS), progression-free survival, and overall survival from distant recurrence to death (OS2) were analyzed in 226 patients with stage I-III uveal melanoma who underwent primary local therapy.
Results
Forty-nine patients (21.7%) had distant recurrences, which occurred most frequently in the liver (87.7%). In a multivariate analysis, local radiotherapy improved RFS among patients with multiple recurrence risk factors relative to excision (not reached vs. 19.0 months, p=0.004). Patients with BRCA1-associated protein-1 (BAP1)‒negative primary tumors showed a longer RFS duration after primary treatments, while those with BAP1-negative metastatic tissues had a shorter OS2 compared to those with BAP1-positive tumors, both not statistically insignificance (RFS: not reached vs. 82.0 months, p=0.258; OS2: 15.7 vs. 24.4 months, p=0.216). Male sex (hazard ratio [HR], 3.79; p=0.012), a short RFS (HR, 4.89; p=0.014), and a largest metastatic tumor linear diameter ≥ 45 mm (HR, 5.48; p=0.017) were found to correlate with worse post-recurrence survival.
Conclusion
Risk factors could be used to classify uveal melanoma cases and subsequently direct individual treatment strategies. Furthermore, metastasectomy appears to contribute to improved survival outcomes.

Citations

Citations to this article as recorded by  
  • Favorable Outcomes of Patients With High-Risk Uveal Melanoma Treated With a Novel Linear Accelerator-Based Frameless Fractionated Stereotactic Radiosurgery
    Louis Cappelli, Mehak M. Khan, Carol L. Shields, Sara E. Lally, Muhammad Sharif, Haisong Liu, Yingxuan Chen, Jade Park, Tingting Zhan, Wenyin Shi
    American Journal of Ophthalmology.2025; 271: 417.     CrossRef
  • Uveal Melanoma: Comprehensive Review of Its Pathophysiology, Diagnosis, Treatment, and Future Perspectives
    Merve Kulbay, Emily Marcotte, Raheem Remtulla, Tsz Hin Alexander Lau, Manuel Paez-Escamilla, Kevin Y. Wu, Miguel N. Burnier
    Biomedicines.2024; 12(8): 1758.     CrossRef
  • Impact of Metastatic Pattern on Survival in Patients with Posterior Uveal Melanoma: A Retrospective Cohort Study
    Tine G. Hindso, Peter S. Jensen, Mette B. Sjøl, Kristoffer Nissen, Camilla W. Bjerrum, Eric von Benzon, Carsten Faber, Steen F. Urbak, Marco Donia, Inge M. Svane, Eva Ellebaek, Steffen Heegaard, Karine Madsen, Jens F. Kiilgaard
    Cancers.2024; 16(19): 3346.     CrossRef
  • Identification of a prognostic six-immune-gene signature and a nomogram model for uveal melanoma
    Binghua Yang, Yuxia Fan, Renlong Liang, Yi Wu, Aiping Gu
    BMC Ophthalmology.2023;[Epub]     CrossRef
  • Prognostic Value of the Radiomics-Based Model in the Disease-Free Survival of Pretreatment Uveal Melanoma: An Initial Result
    Yaping Su, Xiaolin Xu, Fang Wang, Panli Zuo, Qinghua Chen, Wenbin Wei, Junfang Xian
    Journal of Computer Assisted Tomography.2023; 47(1): 151.     CrossRef
  • Uveal melanoma pathobiology: Metastasis to the liver
    Prisca Bustamante, Léo Piquet, Solange Landreville, Julia V. Burnier
    Seminars in Cancer Biology.2021; 71: 65.     CrossRef
  • Malignant uveal melanoma with metastatic recurrence to the pancreas: A case report
    Wei‐Chun Weng, Tzung‐Jiun Tsai, Wen‐Chi Chen, Jin‐Shiung Cheng, Wei‐Chih Sun
    Advances in Digestive Medicine.2021; 8(3): 178.     CrossRef
  • Role of somatic mutations and chromosomal aberrations in the prognosis of uveal melanoma in a Spanish patient cohort
    Paula Silva‐Rodríguez, Manuel Bande, Daniel Fernández‐Díaz, Nerea Lago‐Baameiro, María Pardo, María José Blanco‐Teijeiro, Fernando Domínguez, Lourdes Loidi, Antonio Piñeiro
    Acta Ophthalmologica.2021;[Epub]     CrossRef
  • Clinical features and survival outcomes of ocular melanoma in a multi-ethnic Asian cohort
    Laura Ling Ying Tan, Jiancheng Hong, Wei Lin Goh, Esther Wei Yin Chang, Valerie Shiwen Yang, Eileen Poon, Nagavalli Somasundaram, Mohamad Farid, Anita Sook Yee Chan, Jason Yongsheng Chan
    Scientific Reports.2020;[Epub]     CrossRef
  • ЕФЕКТИВНІСТЬ РАДІОХВИЛЬОВОЇ (3,8 МГЦ) БЛОКЕКСЦИЗІЇ МЕЛАНОМИ ЦИЛІОХОРІОЇДАЛЬНОЇ ЛОКАЛІЗАЦІЇ
    O. V. Khomyakova
    Здобутки клінічної і експериментальної медицини.2020; (3): 173.     CrossRef
  • 10,547 View
  • 231 Download
  • 10 Web of Science
  • 10 Crossref
Close layer
Ruthenium-106 Brachytherapy with or without Additional Local Therapy Shows Favorable Outcome for Variable-Sized Choroidal Melanomas in Korean Patients
Yeona Cho, Jee Suk Chang, Jin Sook Yoon, Sung Chul Lee, Yong Bae Kim, Joo Ho Kim, Ki Chang Keum
Cancer Res Treat. 2018;50(1):138-147.   Published online March 24, 2017
DOI: https://doi.org/10.4143/crt.2016.391
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to report clinical outcomes of ruthenium-106 (106Ru) brachytherapy with or without additional local therapy for choroidal melanomas in Korean patients.
Materials and Methods
A total of 88 patients diagnosed with choroidal melanomas were treated with 106Ru brachytherapy between 2006 and 2012. Patients were divided into two groups according to their tumor height: a large group (≥ 6 mm, n=50) and a small group (< 6 mm, n=38). Most patients in the large group received combined therapy with local excision and/or transpupillary thermotherapy. In general, 85-95 Gy was administered to the apex of the tumor, while 100 Gy was administered to the point 2-6 mm from the outer surface of the sclera for patients undergoing combined therapy.
Results
The median follow-up duration was 30 months. The 3-year local control rate was significantly higher in the small group than in the large group (94% vs. 70%, p=0.047). The free from distant metastasis (FFDM) rate and the overall survival (OS) rate were also higher in patients in the small group (3-year FFDM, 97% vs. 76%; p=0.031 and 3-year OS, 97% vs. 72%; p=0.036). A total of 13 patients underwent enucleation. The eye-preservation rate was also higher in the small group (3-year eye-preservation rate, 94% vs. 70%; p=0.050), and tumor height was a significant prognostic factor for eye-preservation.
Conclusion
106Ru brachytherapy showed favorable outcomes in small choroidal melanomas in Korean patients. Although additional local treatment could improve eye-preservation rate for large tumors, other strategies should be considered for disease control.

Citations

Citations to this article as recorded by  
  • Incidence, risk factors and outcomes of cataract surgery after plaque brachytherapy for posterior uveal melanoma
    Viktor T. Gill, Gustav Stålhammar
    Heliyon.2024; 10(1): e23447.     CrossRef
  • Brachytherapy With 15- Versus 20-mm Ruthenium 106 Plaques Without Verification of Plaque Position Is Associated With Local Tumor Recurrence and Death in Posterior Uveal Melanoma
    Gustav Stålhammar
    International Journal of Radiation Oncology*Biology*Physics.2023; 117(5): 1125.     CrossRef
  • The Role of Ruthenium Compounds in Neurologic Diseases: A Minireview
    Fátima Virgínia Gama Justi, Gabriella Araújo Matos, Juan de Sá Roriz Caminha, Cássia Rodrigues Roque, Edinilton Muniz Carvalho, Márcio Wilker Soares Campelo, Ludmila Belayev, Luiz Gonzaga de França Lopes, Reinaldo Barreto Oriá
    The Journal of Pharmacology and Experimental Therapeutics.2022; 380(1): 47.     CrossRef
  • Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy
    Gilda Cennamo, Daniela Montorio, Luca D’ Andrea, Antonio Farella, Elide Matano, Mario Giuliano, Raffaele Liuzzi, Maria Angelica Breve, Sabino De Placido, Giovanni Cennamo
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Uveal Melanoma: A Review of the Literature and Personal Experiences
    Yong Joon Kim, Christopher Seungkyu Lee, Sung Chul Lee
    Journal of Retina.2021; 6(2): 65.     CrossRef
  • Prognostic Factors and Decision Tree for Long-Term Survival in Metastatic Uveal Melanoma
    Daniel Lorenzo, María Ochoa, Josep Maria Piulats, Cristina Gutiérrez, Luis Arias, Jaume Català, María Grau, Judith Peñafiel, Estefanía Cobos, Pere Garcia-Bru, Marcos Javier Rubio, Noel Padrón-Pérez, Bruno Dias, Joan Pera, Josep Maria Caminal
    Cancer Research and Treatment.2018; 50(4): 1130.     CrossRef
  • 8,639 View
  • 211 Download
  • 5 Web of Science
  • 6 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP